The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | C | Cardiovascular system | |
2 | C01 | Cardiac therapy | |
3 | C01B | Antiarrhythmics, class I and III | |
4 | C01BB | Antiarrhythmics, class Ib |
Code | Title | |
---|---|---|
C01BB01 | Lidocaine | |
C01BB02 | Mexiletine | |
C01BB03 | Tocainide | |
C01BB04 | Aprindine |
Active Ingredient | Description | |
---|---|---|
Lidocaine |
Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane. |
|
Mexiletine |
Mexiletine blocks sodium channels with a stronger potency in situations of excessive burst of action potentials (use-dependent block) and/or prolonged depolarization (voltage-dependent block), as occurring in diseased tissues, rather than on physiological excitability (resting or tonic block). Mexiletine is, therefore, mostly active on muscle fibres subject to repeated discharges (such as skeletal muscles). It improves myotonic symptoms by decreasing muscle stiffness through reduction of the delay of muscle relaxation. |
Title | Information Source | Document Type | |
---|---|---|---|
NAMUSCLA Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
XYLOCARD Solution for injection | Health Products and Food Branch (CA) | MPI, CA: SPM |